Antipsychotic-induced weight gain (AIWG) may result in the metabolic syndrome in schizophrenia (SCZ) patients. Downstream variants of the melanocortin-4 receptor (MC4R) gene have been associated with obesity in various populations. Thus, we examined single-nucleotide polymorphisms (SNPs) in the MC4R region for association with AIWG in SCZ patients. Four SNPs (rs2229616, rs17782313, rs11872992 and rs8087522) were genotyped in 224 patients who underwent treatment for SCZ and were evaluated for AIWG for up to 14 weeks. We compared weight change (%) across genotypic groups using analysis of covariance for three SNPs (r 2 p0.8).
Introduction
Schizophrenia (SCZ) is a debilitating psychiatric disease that affects 1% of the general population. The widely prescribed atypical antipsychotic medications are effective in treating core positive symptoms of SCZ. Despite the success of atypical antipsychotic drugs in symptom reduction, their clinical use remains burdensome. This is due to their association with substantial weight gain and the metabolic syndrome. The metabolic syndrome is composed of several factors, including insulinemia, abdominal obesity and hypertension. 1 Both severe weight gain and the metabolic syndrome can have potentially fatal consequences, including development of diabetes mellitus and coronary heart disease. 2 Studies have confirmed that the rates of the metabolic syndrome in SCZ samples are between 40 and 50%. [3] [4] [5] The underlying mechanisms of onset of weight gain and the metabolic syndrome in SCZ patients have yet to be elucidated. Approximately 30-40% of patients experience substantial weight gain and the metabolic syndrome after initial treatment with second-generation antipsychotic drugs. Discovery of genetic factors associated with metabolic side effects can lead to improved treatment regimes and novel targets for drug development.
Genetic mechanisms are among the strongest known factors in regulating second-generation antipsychotic (SGA)-induced weight gain. A high inter-individual variability exists between patients who are treated with SGAs in terms of the side effect profile. This is demonstrated by the finding that up to 30% of patients develop weight gain and the metabolic syndrome, whereas some patients do not. 2 One of the strongest reports supporting genetic regulation of this side effect is from the recent twin and sibling study that reported heritability of SGA-induced weight gain is between (h 2 ¼ 0.6-0.8). 6 Thus, pharmacogenetic-based algorithms have a high potential to identify individuals who are at risk for development of antipsychotic-induced weight gain (AIWG). These, in turn, can greatly aid in the decisionmaking process for antipsychotic treatment.
In general, obesity has become an epidemic in North America. 7 The pathophysiology of appetite and weight regulation is an area that is being extensively investigated in order to develop counteracting strategies and treatment. The leptinergic system has been reported to be heavily involved in physiological food intake and weight regulation. In an intact homeostatic feedback system, leptin activates pro-opiomelanocortin neurons in the arcuate nucleus of the hypothalamus. The pro-opiomelanocortin peptide is the precursor for neuropeptides, including a-melanocytestimulating hormone (a-MSH). 8 a-MSH activates the melanocortin receptor-4 (MC4R), and the signals from MC4R-expressing neurons are hypothesized to modulate various pathways through downstream effectors that result in energy expenditure. 9 Animal model studies that used gene targeting found that mice lacking the MC4R receptor showed a mature-onset obesity syndrome, associated with metabolic abnormalities such as hyper-insulinemia and hyperglycemia. [10] [11] [12] Furthermore, mutations of MC4R can cause monogenic obesity in humans. 13 Recently, a more common genetic variant located 188 kb downstream from the MC4R gene (rs17782313) has been associated with increased fat mass, weight and waist circumference. 14, 15 The MC4R gene was recently identified as a gene for obesity susceptibility in a genome-wide association study (GWAS) of 249 796 individuals. 15 The minor C-allele of this MC4R variant has previously been associated with higher intake of total energy and dietary fat, resulting in greater long-term weight change in a healthy population.
14 Another well-studied polymorphism, the MC4R 103I (rs2229616) marker, has been associated with decreased waist circumference along with other measures of the metabolic syndrome (decreased glycosylated hemoglobin). 16, 17 Interestingly, the same rs17782313 marker was not significantly associated with AIWG in a sample of pediatric and adolescent patients who were naïve to antipsychotic medication using a GWAS approach. 18 However, our group, in collaboration with Malhotra et al, 18 discovered and replicated an association between another marker at MC4R rs489693 and AIWG. The discovery cohort in this study consisted of antipsychotic-naïve adolescents who were administered one of several antipsychotics (olanzapine, risperidone, quetiapine or aripiprazole) and weight gain was measured for up to 12 weeks. The rs489693 marker was also associated with weight gain in a sample comprising SCZ patients who had been given clozapine with no prior second-generation antipsychotic treatment. The association of rs489693 was again replicated in a third sample that consisted of SCZ patients who were prescribed antipsychotic treatments in a naturalistic setting.
Taking into consideration the strong positive associations of MC4R polymorphisms with obesity and AIWG, we evaluated whether additional MC4R gene polymorphisms are associated with AIWG. In this study, we investigated the possible association between rs17782313 and rs2229616, which have been consistently implicated with obesity in the literature. [14] [15] [16] [17] In addition, we also investigated rs8087522 and rs11872992, which are both located in the promoter region of the MC4R gene.
Materials and methods

Subjects
A total of 224 patients with chronic SCZ or schizoaffective disorder were included in this study, and sample characteristics have been described previously. 19 Approval from the institutional ethics committee and informed consent were obtained for all patients. Patients were primarily recruited from three different sites. Sample-A: Charité University Medicine (Berlin, Germany) (DJ Müller, n ¼ 93). Patients were diagnosed with either SCZ or schizoaffective disorder according to the DSM-IV and ICD-10 criteria. They were given antipsychotic medication and assessed for up to 6 weeks ( Table 1) . Sample-B: Case Western Reserve University in Cleveland (Ohio, USA) (HY Meltzer, n ¼ 76). DSM III-Rdiagnosed SCZ patients were longitudinally studied and were either treatment-refractory or intolerant to treatment with typical antipsychotics. Prior to treatment with clozapine, patients underwent a washout period of 2-4 weeks during which no medications were given unless deemed clinically essential by the physician. The dosage of clozapine was not fixed and serum levels were monitored to ascertain compliance. Patients were treated with clozapine for a minimum of 6 weeks and weight change (%) was calculated from baseline weight (for details see Masellis et al 20 and Basile et al 21 ). Sample-C: Hillside Hospital in Glen Oaks (New York, USA) (JA Lieberman, n ¼ 55). DSM-IV-diagnosed patients with chronic SCZ or schizoaffective disorder that had shown suboptimal response to previous atypical antipsychotic drug treatment were included in this study. Despite previous treatment, these patients had continued to express positive symptoms and poor cognitive functioning over a period of 2 years. In a 14-week double-blind study, patients were randomly assigned to receive clozapine (500 mg day À1 ), olanzapine (20 mg day À1 ), risperidone (8 mg day . Patient ethnicity was ascertained using self-reported ancestry information over the last three generations.
Genetic analysis
Venous blood (10-20 ml) was obtained from study participants and DNA was extracted at the Centre for Addiction and Mental Health using the high-salt method. 25 All singlenucleotide polymorphisms (SNPs; rs17782313, rs8087522, rs11872992 and rs2229616; Figure 1 ) were genotyped using TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA, USA). PCR was performed in a final volume of 10 ml, using 20 ng genomic DNA and 1 Â TaqMan Universal PCR master mix. The following conditions were applied for amplification: 95 1C for 10 min, followed by 50 cycles of 92 1C for 15 s and 60 1C for 1 min. Alleles were called using the Allelic Discrimination module of the Sequence Detection software supplied with the ABI model 7500 machine. Genotyping was performed blind to the subject's weight gain status. Ten percent of the sample was randomly re-genotyped for quality control and 100% concordant genotype calling was observed.
Data analysis
Statistical analyses were performed for individual SNP using SPSS 15.0. Categorical variables were tested by w 2 -test. Continuous variables were tested by analysis of variance or covariance. Weight change (%) from baseline was compared across the genotypic categories by analysis of covariance using duration of treatment as a covariate. Distribution of age and sex across genotypic groups was assessed. If either age or sex, or both, showed a significant effect, they were included as covariates in the analysis of covariance. Haplotype blocks were examined and weight change (%) with UNPHASED 3.1. 25 Only haplotypes with frequencies greater than 5% were included in the analyses. Linkage disequilibrium and Hardy-Weinberg equilibrium were determined using Haploview 4.1.
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Power calculations were performed using Quanto 1.2.4. Assuming a minor allele frequency of 0.20 in a sample size of n ¼ 224, in an additive model we had more than 80% power to detect a mean weight difference of 1.5% between carriers and non-carriers of the risk genotype. 27 Electrophoretic mobility-shift assay We performed an electrophoretic mobility-shift assay (EMSA) as described by Tiwari et al. 19 We initially analyzed in silico for presence of binding sites using the Genomatix MatInspector program. Biotin-labeled and unlabeled double-stranded oligonucleotides for each allele of rs8087522 (A and G), and unlabeled oligonucleotides with the specific consensus-binding site for the transcription factor for Paired Related Homeobox 2 (PRX2) 28 and MSH homeobox 2 (MSX2), 29 were synthesized. Nuclear extract was prepared from SH-SY5Y neuroblastoma cells (ATCC: CRL2266, Manassas, VA, USA) using the NE-PER Nuclear and cytoplasmic extraction kit (Pierce, Rockford, IL, USA). The complementary pairs of nucleotides were suspended in STE Buffer (10 mM Tris (pH 8.0), 50 mM NaCl, 1 mM EDTA) and annealed using a thermocycler (Step-1: 95 1C for 5 min; MC4R and antipsychotic-induced weight gain
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Step-2: 95 1C (À1 1C/cycle, 70 times);
Step-3: HOLD at 4 1C).
The re-annealed double-stranded oligonucleotides (20 fmol) were incubated with 2 ml of the nuclear extract, 1 Â binding buffer, 2.5% glycerol, 5 mM MgCl2, 50 ng ml À1 poly-(dIdC) and 0.05% NP-40 for 20 min at room temperature. For the competition experiments, unlabeled oligonucleotides at 200-fold molar excess (4 pmol) were pre-incubated with the nuclear extract before adding the biotin-labeled oligonucleotides. DNA-protein complexes were fractioned on 5% polyacrylamide gel in 0.5 Â TBE for 35 min. Complexes were electrotransferred to a nylon membrane at 380 mA for 45 min, and cross-linked at 120 mJ cm À2 for 45 s. The biotinylated oligonucleotides were detected by chemiluminescence using the Chemiluminescent nucleic acid detection module of the Light Shift Chemiluminescent EMSA kit (Pierce). The processed nylon membrane was exposed to an X-ray film for 45 s.
Results
Genetic analysis
The demographic characteristics of the study sample are presented in Table 1 . Significant differences in clinical variables were observed among clinical sites; however, similar rates of change in weight were observed ( Table 1) . The three SNPs, rs17782313, rs8087522 and rs11872992, analyzed in this study were in Hardy-Weinberg equilibrium (P40.05; Table 2 ). The rs2229616 SNP was monomorphic in our sample and thus was excluded from our statistical analyses. Duration of treatment varied across clinical sites and thus was entered as a covariate in all association analysis.
In the total sample, we observed no significant association between genotypes and weight change (Table 2) . However, our sample consisted of patients of different ethnicities (mostly of European and African ancestry) and receiving drugs with different propensities to cause weight gain. Clozapine and olanzapine have been reported to be associated with the highest risk of clinically significant weight gain and show overlapping side-effect profiles. 30 Thus, we performed a sub-analysis stratifying patients by their self-reported ethnicities and whether they received clozapine or olanzapine. Patients classified in the African American group were too low in number to allow analysis with sufficient power. In the patients of European ancestry who received either clozapine or olanzapine, no significant genotypic association was observed for rs11872992 and rs17782313, whereas a non-significant trend was found for the rs8087522 marker, where the GA or AA genotypes gained more weight than GG homozygotes (P ¼ 0.11) ( Table 2) .
Both clozapine and olanzapine have a significantly higher propensity to induce weight gain compared with other antipsychotic drugs. 30 We stratified the European-ancestry sample by individual drug type to uncover associations with weight gain in relation to these two individual drugs. In patients of European ancestry who were treated with clozapine (n ¼ 69), we found that carriers of the MC4R rs8087522 'A'-allele (AA þ AG) gained significantly more weight (5.38%±5.7) than the GG homozygotes (2.43%±4.3; P ¼ 0.027) (Table 3) . However, these results were not significant after taking into account the multiple SNPs that we have analyzed (3 SNPs, Bonferroni-corrected, P ¼ 0.081). Allelic analyses also suggested that the 'A'-allele carriers gained more weight (5.60% ± 5.4) than carriers of the 'G'-allele (3.3% ± 5.4; P ¼ 0.04) ( Table 3 ). There were no significant allelic or genotypic associations observed with weight gain in patients of African American ancestry, owing to the very small sample size.
In the allelic analyses in the European sub-sample, the minor C-allele of the rs17782313 marker, a trend for association (P ¼ 0.09) with weight gain was observed in the combined sample of clozapine-and olanzapine-treated patients. A non-significant trend for allelic association was also observed with rs11872992, whereas no allelic association was observed for the rs8087522 marker (Table 3) despite its modest association in the genotypic analyses. Linkage disequilibrium was calculated using Haploview 4.1. D'-values were high for all pairwise comparisons among the SNPs and r 2 was low ( Figure 1 ). Two marker haplotype analyses were conducted and no associations were found for the three SNPs and weight gain (P40.05) (Figure 1 ).
Electrophoretic mobility-shift assay
The SNP rs8087522, associated with clozapine-induced weight gain, is present in the promoter region of MC4R and is in the vicinity of a genomic region that has been reported to code for transcription factor-binding sites, according to the University of California Santa Cruz (UCSC) genome browser. EMSA is an in vitro method to assess DNAprotein interactions that reflect transcription factor-binding sites, which may be relevant to gene expression.
An in silico prediction of transcription factor binding using a 31-bp oligonucleotide surrounding the SNP rs8087522 was performed using Mat Inspector (Genomatix, 2010). Presence of the A-allele was predicted to bind to 20 transcription factors. The transcription factors PRX2-binding protein-1 (PRX2, matrix similarity of 1.00) and MSX2 protein (matrix similarity of 0.995) had the highest similarity with the region encompassing the A-allele (Table 4) . Therefore, these two transcription factors were chosen for further analysis. An EMSA was performed and putative binding of a nuclear protein to the A-allele was observed (Figure 2 ). Oligonucleotides containing specific binding sites for transcription factors PRX2 and MSX2 were unable to compete out the labeled oligonucleotide with the A-allele, indicating that these may not be the transcription factors binding at this site (Figure 2) . Binding of nuclear protein to the G-allele was likely to be result of non-specific binding as the unlabeled G-allele containing the oligonucleotide could not disrupt this binding.
Discussion
In this study, based on the strong biological rationale for MC4R in weight regulation, we investigated MC4R polymorphisms for their potential roles in AIWG. We investigated rs17782313 and rs2229616, which have been associated with obesity previously, 14, 20 as well as two SNPs in the MC4R promoter region (rs8087522 and rs11872992) that could have potential roles in gene expression.
The rs2229616 marker has been reported to be mildly protective against weight gain in the general population; 16, 17 however, it was monomorphic in our sample and was therefore excluded from statistical analyses. We did not observe any significant associations with the rs17782313 and rs11872992 polymorphisms and AIWG in the total sample set. There was no significant association between rs17782313 or rs11872992 and weight gain in a subset of European-ancestry patients who received clozapine or olanzapine treatment. Notably, the rs17782313 minor C-allele had a non-significant trend for association with weight gain in our allelic analyses in our European-ancestry patients (P ¼ 0.09). This same allele has been previously associated with increased body mass index in a GWAS of 16 876 individuals of European descent. 31 However, the rs17782313 marker was not significantly associated with weight gain or metabolic parameters in the recent GWAS assessing a pediatric drug-naïve population exposed to antipsychotic medication. 18 Given that our hypothesisdriven study design and sample were different from those of the pediatric GWAS investigation by Malhotra et al, 18 direct comparisons are not possible. Overall, more work is needed to elucidate the role of this SNP in AIWG.
By contrast, we observed a modest association with the rs8087522 variant and AIWG in the subset of European patients who were exposed to clozapine. Our genetic results indicated that patients of European American ancestry who were carriers of the rs8087522 AA genotype were more likely to gain weight when given clozapine for treatment. In the allelic analysis, a modest trend of association with weight gain was found for carriers of the A-allele. This polymorphism is in the promoter region of MC4R (Figure 1) , suggesting a potential regulatory role for transcription factor binding. In order to discern the functional relevance of this marker, we performed in silico predictions and observed that several transcription factors bind to the A-allele. Using EMSA we provide suggestive evidence that the rs8087522 A-allele, but not the G-allele, is bound by a yet unknown nuclear protein, and thus may influence MC4R gene expression.
To our knowledge, this is the first study investigating the role of the rs8087522 marker in AIWG. The limitations of the study include a relatively small sample size, compared with other studies, but it is important to note that we have sufficient power. One caveat with our sample is that patients in some sub-samples were not drug-naïve when they entered our study. Thus, they may have already gained weight owing to prior antipsychotic exposure. Despite this, clozapine, the antipsychotic with the highest risk for weight gain, was administered for the first time to a substantial number of A-allele G-allele 5) and G-allele (lanes 6-8). In the competition experiment, using 200-fold excess of unlabeled A-allele containing an oligonucleotide, binding is significantly reduced, suggesting that binding of this nuclear protein is specific to the A-allele. We tested two known transcription factors (PRX and MSX1) for binding to the A-allele. Oligonucleotides containing specific binding sites for these transcription factors (lanes 4 and 5) were unable to complete out the A-allele. EMSA, electrophoretic mobility-shift assay; MSX, MSH homeobox; PRX, Paired Related Homeobox. MC4R and antipsychotic-induced weight gain NI Chowdhury et al patients (every patient in Sample-B), and our analyses showed that these patients did gain a considerable amount of weight.
In this study, we report a nominally significant association between clozapine-induced weight gain and the rs8087522 variant in our European American-ancestry sample. Furthermore, antipsychotic-induced side-effect profiles vary across ethnicities, and we did not have sufficient power to detect an effect for AIWG in our African American-ancestry sample. Further investigation of MC4R gene variants in African Americans is warranted.
Our collaborative group 18 reported that the rs489693 marker is associated with AIWG in three separate samples. The region where this marker is located has been highlighted in several GWASs regarding obesity. 14, 15 The rs489693 is located 190 kb downstream from the MC4R gene and has no known functional relevance. There is no gene located in the region, but the variant has been associated with weight gain in the general population. It may be controlled by one or more remote regulatory sites located at considerable distance from rs489693 (for example, chromosomal folding). 32 The rs489693 marker may also be linked to another 'true' marker that is the actual biological regulator of changes in weight gain. We also examined possible combinations of markers across the MC4R that were significant either in the study by Malhotra et al 18 or within our Toronto-based AIWG samples. There were no significant findings for these marker combinations.
To summarize, we did not replicate the reported association of rs17782313 with obesity 14, 15, 31 in AIWG. Similarly, we found no association with the rs11872992 SNP, which is located within the promoter region of MC4R, and AIWG. A strong biological rationale remains for the study of MC4R and metabolic parameters, including weight gain. The MC4R has a significant regulatory role in food intake and energy homeostasis. Furthermore, the MC4R genetic findings may be used in an attempt to define new targets for discovery of novel medications that do not have severe weight-gain side effects. A recent study reported that an MC4R agonist has potent anti-obesity efficacy in a rodent model. 11 Furthermore, recent studies have shown that in some cases the MC4R protein, if altered by mutation, is unable to reach the plasma membrane as the receptor may misfold in the endoplasmic reticulum, and these defective MC4R proteins are therefore targeted for degradation. 33 The authors suggest that drugs, which improve MC4R folding or decrease the endoplasmic reticulum-associated degradation of the receptor, may treat some forms of hereditary obesity. Understanding the common variants of the MC4R gene may also have implications in drug development for general obesity as well as AIWG.
In conclusion, we report a nominally significant association between rs8087522 and AIWG, and we found that this SNP affects potential transcription factor-binding sites, which may result in functional effects. A recent case-control study reported no association between the rs8087522 and high weight. 34 Our overall findings still suggest that the rs8087522 marker in the MC4R gene may be of interest for further investigation in AIWG and weight regulation in general.
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